🔍

SHALBY - Shalby

📊 NSE: SHALBY 🏢 Healthcare 📅 Last Updated: 12/14/2025 13:06

📢 Recent Corporate Announcements

Shalby Ltd Faces ₹4.14 Crore Tax Demand Following ITAT Order

🔴 NEGATIVE ⭐ 4/10

LEGAL 📅 11 Apr 2026, 06:43 PM

Shalby Limited has received an adverse order from the Income Tax Appellate Tribunal (ITAT), Ahmedabad Bench, regarding a tax dispute. The tribunal dismissed the company's appeal and upheld a tax demand of ₹4.14 crore. The issue relates to the issuance of unquoted shares at a premium by a subsidiary, Shalby Surat Hospital Pvt. Ltd., prior to its demerger, which was added to income under Section 68. While the company intends to contest this order at higher forums, it currently represents a confirmed tax liability.

ITAT Ahmedabad Bench dismissed Shalby's appeal, resulting in a ₹4.14 crore tax demand.
The dispute involves share premium additions made under Section 68 of the Income Tax Act from a 2017 assessment.
The order was passed on March 16, 2026, and received by the company on April 10, 2026.
Management plans to contest the ruling at appropriate legal forums and believes the merits are in their favor.

💡 Investors should monitor whether the company makes a financial provision for this ₹4.14 crore demand in the next quarterly results. While the amount is not large enough to impact long-term fundamentals, it highlights ongoing litigation risks.

Shalby Limited Receives Adverse ITAT Order with Tax Demand of ₹4.14 Crore

🔴 NEGATIVE ⭐ 4/10

LEGAL 📅 11 Apr 2026, 06:30 PM

Shalby Limited has received an adverse order from the Income Tax Appellate Tribunal (ITAT) regarding a tax dispute dating back to 2017. The tribunal has disallowed the company's appeal and upheld a tax demand of ₹4.14 crore related to share premiums issued by a subsidiary before its demerger. The Assessing Officer had previously classified these premiums as unexplained income under Section 68 of the Income Tax Act. While the company intends to contest the order at higher forums, this ruling represents a legal setback in a long-standing litigation matter.

ITAT Ahmedabad Bench passed an order against the company demanding ₹4.14 crore.
The dispute involves share premium valuation by Shalby Surat Hospital Pvt. Ltd. prior to its demerger.
The Assessing Officer added the premium to taxable income under Section 68 vide an order dated December 28, 2017.
Company received the formal order on April 10, 2026, following the tribunal's decision on March 16, 2026.
Management maintains that there is no immediate financial implication as they plan to contest the order at appropriate forums.

💡 Investors should monitor whether the company creates a financial provision for this ₹4.14 crore demand in the next reporting cycle. While the amount is not materially large for Shalby, the outcome of further appeals will be key to resolving this legacy tax liability.

Shalby Issues USD 13.27 Million SBLC for US Step-Down Subsidiary

🟡 NEUTRAL ⭐ 6/10

OTHER 📅 09 Apr 2026, 03:16 PM

Shalby Limited has issued a Standby Letter of Credit (SBLC) for an amount up to USD 13.27 million through IndusInd Bank. The beneficiary of this financial guarantee is Shalby Advanced Technologies, Inc. (SAT Inc.), which is the company's step-down subsidiary based in the USA. This move is intended to help the overseas unit secure credit facilities for its operational requirements. While the company expects no immediate material financial impact on its own operations, it represents a significant financial commitment to its international expansion.

Issuance of Standby Letter of Credit (SBLC) totaling up to USD 13.27 million
Beneficiary is Shalby Advanced Technologies, Inc., a USA-based step-down subsidiary
Financial facility facilitated through IndusInd Bank Limited
Aims to assist the subsidiary in obtaining credit facilities for business needs
Transaction confirmed to be at arm's length with no promoter group interest

💡 Investors should monitor the operational progress of the US subsidiary, as the parent company has now increased its contingent liability to support the unit's creditworthiness. No immediate portfolio changes are necessary based on this routine financial support disclosure.

Shalby Submits Quarterly SEBI Compliance Certificate for Period Ended March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Apr 2026, 03:43 PM

Shalby Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited (the company's RTA), confirms that share certificates received for dematerialization during the quarter ended March 31, 2026, have been processed. This is a standard administrative filing required by all listed companies in India to maintain updated shareholding records with depositories like NSDL and CDSL. The filing indicates the company is adhering to its routine regulatory reporting timelines.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Share Transfer Agent (RTA) KFin Technologies Limited.
Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Verification of dematerialized and rematerialized securities completed for the reporting period.

💡 This is a routine regulatory filing with no impact on company fundamentals. No action is required from investors based on this announcement.

Shalby Limited to Close Trading Window from April 1, 2026, for Q4 and Annual Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 12:08 PM

Shalby Limited has announced the closure of its trading window for all insiders starting Wednesday, April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of audited financial results for the fourth quarter and the full year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are officially announced to the stock exchanges. This is a standard regulatory procedure for listed companies to prevent insider trading during the period when price-sensitive information is being finalized.

Trading window closure begins on April 1, 2026, for all designated insiders.
Closure is related to the upcoming Audited Financial Results for Q4 and FY 2025-26.
The window will reopen 48 hours after the official declaration of the financial results.
The notice follows the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Company insiders have been advised to refrain from trading in Shalby securities during this period.

💡 This is a routine administrative filing and does not impact the company's fundamentals; investors should monitor for the upcoming Q4 result date announcement.

Shalby Shareholders Approve Re-appointment of Independent Director with 99.49% Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Mar 2026, 12:25 PM

Shalby Limited has successfully passed a special resolution via postal ballot for the re-appointment of Mr. Shyamal Shivkumar Joshi as an Independent Director. The resolution received overwhelming support with 99.49% of the total votes polled in favor. The new five-year term is set to commence on May 17, 2026, and conclude on May 16, 2031. While the promoter group supported the move entirely, a segment of public institutional and non-institutional shareholders voted against the proposal.

Special resolution passed for re-appointment of Mr. Shyamal Shivkumar Joshi for a second 5-year term starting May 2026.
Total votes polled amounted to 8,07,30,111, representing approximately 74.74% of the total outstanding shares.
The resolution was supported by 99.49% of polled votes (8,03,19,570 shares) and opposed by 0.51% (4,10,541 shares).
Promoter group voted 100% in favor, while participating public institutions (3,50,749 votes) voted 100% against.
Public non-institutional shareholders showed mixed sentiment with 59.06% of their polled votes against the resolution.

💡 This is a routine governance matter ensuring board continuity. Investors should monitor if the institutional dissent reflects broader concerns regarding board independence or performance.

Shalby Launches Advanced Oncology and Radiotherapy Department at Krishna Shalby Hospital

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 23 Mar 2026, 10:45 AM

Shalby Limited has announced the inauguration of a specialized Oncology Department at its Krishna Shalby Hospital in Ahmedabad. This new facility includes advanced Radiotherapy services, allowing for comprehensive cancer treatment under one roof. The department is staffed by a multidisciplinary team of medical, radiation, and surgical oncologists to provide integrated care. This expansion into high-specialty services is expected to enhance the hospital's service mix and competitive positioning in the Ahmedabad region.

Inauguration of a new Oncology Department at Krishna Shalby Hospital, Ahmedabad
Addition of advanced Radiotherapy facilities to provide integrated cancer care
Deployment of a multidisciplinary team including medical, radiation, and surgical oncologists
Strategic focus on providing comprehensive diagnosis and treatment at a single location to improve patient outcomes

💡 Investors should view this as a positive development as oncology is a high-margin specialty that can drive higher Average Revenue Per Occupied Bed (ARPOB). Monitor the company's upcoming quarterly results for improvements in specialized treatment volumes.

Shalby Launches Advanced Oncology and Radiotherapy Department at Surat Hospital

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 09 Mar 2026, 12:52 PM

Shalby Limited has inaugurated a comprehensive Oncology Department at its Surat multi-specialty hospital. The new facility includes advanced radiotherapy services, enabling the hospital to provide integrated cancer care across medical, surgical, and radiation oncology. This expansion targets the South Gujarat region, aiming to provide specialized diagnosis and treatment under one roof. The addition of high-margin oncology services is expected to enhance the hospital's service mix and potentially improve its Average Revenue Per Occupied Bed (ARPOB).

Inauguration of a dedicated Oncology Department at Shalby Multi-Specialty Hospital, Surat
Introduction of advanced Radiotherapy facilities for comprehensive cancer treatment
Integrated care model featuring medical, radiation, and surgical oncology teams
Strategic expansion to capture demand for specialized cancer care in the South Gujarat region

💡 Investors should view this as a positive operational development that could boost high-margin revenue for the Surat unit. Monitor future quarterly results for improvements in ARPOB and occupancy driven by these specialized services.

Shalby Subsidiary PK Healthcare Receives NABH Accreditation Valid Until 2030

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 03 Mar 2026, 05:05 PM

Shalby Limited's subsidiary, PK Healthcare Private Limited (Shalby International Hospitals) located in Gurugram, has been granted accreditation by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). The accreditation follows the 6th Edition Standards, which focus on patient safety, clinical governance, and risk management. This certification is valid for a period of four years, extending until 2030. Such accreditations are critical for healthcare providers to maintain quality benchmarks and attract corporate and insurance-linked patients.

PK Healthcare Pvt Ltd (Gurugram) granted NABH accreditation under the rigorous 6th Edition Standards.
The accreditation is valid for a long-term duration until the year 2030.
Framework emphasizes patient safety protocols, clinical governance, and continuous quality improvement.
Accreditation strengthens the hospital's position in evidence-based clinical care and infection control.

💡 Investors should view this as a positive operational milestone that validates the quality of healthcare services at Shalby's Gurugram facility. This accreditation is likely to improve the hospital's reputation and operational efficiency, supporting long-term revenue growth.

Shalby Discontinues SOCE Operations in Rajkot and Lucknow Due to Economic Inviability

🟡 NEUTRAL ⭐ 4/10

OTHER 📅 02 Mar 2026, 07:17 PM

Shalby Limited has announced the closure of its Shalby Orthopedics Centre of Excellence (SOCE) operations in Rajkot and Lucknow, effective January 31 and February 15, 2026, respectively. The combined revenue contribution from these units was minimal, totaling approximately 0.75% of the company's FY2024-25 turnover. Management cited economic inviability as the primary reason for this strategic exit to maintain financial parameters. However, the company will continue to operate its Outpatient Department (OPD) services in both cities.

Closure of SOCE operations in Rajkot (Jan 31, 2026) and Lucknow (Feb 15, 2026) due to economic inviability.
Lucknow unit contributed ₹5.69 crore (0.65% of turnover) in FY2024-25.
Rajkot unit contributed ₹0.91 crore (0.10% of turnover) from July 2024 to March 2025.
Combined impact on total turnover is negligible at less than 1%.
OPD services will remain operational in both cities to maintain market presence.

💡 This is a minor portfolio rationalization move to eliminate loss-making or low-margin units. Investors should monitor if this leads to improved operating margins in the upcoming quarters.

Shalby Increases Stake in Subsidiary PK Healthcare to 91.13% via Rs 59.6 Cr Rights Issue

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 28 Feb 2026, 05:08 PM

Shalby Limited has increased its stake in its subsidiary, PK Healthcare Private Limited (PKHPL), from 87.26% to 91.13%. The company invested approximately Rs 59.60 crore by subscribing to 5.96 crore equity shares at a price of Rs 10 per share through a rights issue. The capital infusion will be utilized by PKHPL for debt repayment and working capital requirements. PKHPL, which focuses on the Delhi/NCR healthcare market, reported a turnover of Rs 91.19 crore in FY 2024-25.

Acquired 5,96,01,950 equity shares of PK Healthcare at Rs 10 per share
Total investment amount stands at Rs 59,60,19,500
Shalby's shareholding in PKHPL increased from 87.26% to 91.13%
Funds will be used by the subsidiary for debt repayment and working capital
PKHPL's turnover grew from Rs 67.36 crore in FY23 to Rs 91.19 crore in FY25

💡 This move consolidates control and helps deleverage a key subsidiary in the high-growth Delhi/NCR region. Investors should monitor if this capital infusion leads to improved consolidated margins for Shalby in the coming quarters.

Shalby Q3 FY26: Consolidated PAT Turns Positive at ₹1.3 Cr; MedTech Revenue Jumps 29% YoY

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 18 Feb 2026, 04:25 PM

Shalby Limited reported a marginal 0.6% YoY decline in consolidated revenue to ₹279.4 crores for Q3 FY26, while consolidated PAT turned positive at ₹1.3 crores compared to a loss in the previous year. The core hospital business faced headwinds with a 2.6% revenue decline and lower occupancy of 44%, primarily due to ongoing negotiations with major insurance providers. Conversely, the MedTech segment showed strong momentum with 29% revenue growth and achieved EBITDA breakeven for the first time. The company maintains a stable balance sheet with a net debt of ₹408 crores and a low gearing ratio of 0.41x.

Consolidated PAT improved to ₹1.3 crores from a loss of ₹3 crores in the same quarter last year.
MedTech segment revenue grew 29% YoY to ₹30.38 crores, with EBITDA turning positive at ₹0.7 million.
Hospital standalone revenue declined 2.6% YoY to ₹221 crores with occupancy dropping to 44% from 46%.
ARPOB (Average Revenue Per Occupied Bed) saw a marginal increase of 1.1% YoY to ₹43,171.
Shalby International (Gurgaon) reported revenue of ₹23.9 crores with 51% contribution from international patients.

💡 Investors should monitor the recovery in hospital occupancy once insurance negotiations are finalized and track the scalability of the now-profitable MedTech division. The stock remains a watch as the company transitions its medical implant business from a turnaround to a growth phase.

Shalby Limited Releases Q3 FY 2025-26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 12 Feb 2026, 06:24 PM

Shalby Limited has officially released the audio recording of its earnings conference call for the third quarter of FY 2025-26, held on February 12, 2026. The call discussed the unaudited standalone and consolidated financial results for the period ended December 31, 2025. This disclosure is in compliance with Regulation 30 and 46(2) of the SEBI (LODR) Regulations, 2015. Investors can now access the management's commentary and responses to analyst queries via the provided web link.

Earnings conference call for Q3 FY 2025-26 conducted on February 12, 2026, at 4:00 p.m.
Discussion covered both standalone and consolidated unaudited financial results for the quarter ended December 31, 2025.
Audio recording link made available on the company's official website for public access.
Compliance filing follows the initial intimation provided to exchanges on February 2, 2026.

💡 Investors should listen to the recording to understand management's outlook on hospital occupancy rates and the growth of their implants business.

Shalby Q3 FY26 Results: Consolidated PAT Turns Positive at ₹13 Mn Despite Flat Revenue

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 08:53 PM

Shalby Limited reported a mixed performance for Q3 FY26, with consolidated revenue remaining nearly flat at ₹2,794 million, a marginal 0.6% YoY decline. The company successfully turned around its consolidated bottom line, reporting a PAT of ₹13 million compared to a loss of ₹29.9 million in the year-ago period. However, operational metrics showed weakness, with inpatient counts down 7% and surgery counts down 8.5% YoY. Standalone EBITDA margins also faced significant pressure, contracting to 16.0% from 21.5% in Q3 FY25.

Consolidated PAT improved to ₹13 million from a loss of ₹29.9 million in Q3 FY25.
Standalone EBITDA margins compressed by 550 bps YoY to 16.0% due to higher operating expenses.
Total surgery counts declined by 8.5% YoY to 6,833, while ARPOB saw a marginal increase of 1.1% to ₹43,171.
MedTech (Implant Business) contributed 10.88% to consolidated revenue, amounting to ₹303.8 million.
Consolidated net debt stood at ₹4,086 million as of December 2025 with an annualized ROCE of 6.7%.

💡 Investors should exercise caution due to the decline in operational volumes and significant margin compression in the core standalone business. While the turnaround in consolidated PAT is positive, the high debt-to-equity ratio of 0.41x and low ROCE warrant a watchful approach.

Shalby Limited Grants 13,000 ESOPs to Employees Under 2021 Scheme

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 08:44 PM

Shalby Limited has approved the grant of 13,000 stock options to eligible employees under its 2021 ESOP Scheme. The grant is split into 11,000 options at an exercise price of ₹10 and 2,000 options at ₹100 per share. These options carry a vesting period of two years and must be exercised within one year of vesting. Importantly, the company stated that there will be no increase in paid-up share capital as the shares are sourced from the secondary market via a trust.

Grant of 13,000 total stock options to eligible employees on February 11, 2026
Exercise price set at ₹10 for 11,000 options and ₹100 for 2,000 options
Vesting period of 2 years from the date of grant with a 1-year exercise window thereafter
Zero equity dilution as shares are channelized from the secondary market through a Trust

💡 This is a routine corporate action for employee retention with no impact on equity dilution. Investors should remain focused on the company's operational performance and hospital occupancy rates.

View All SHALBY Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 5.5% YoY to INR 289.9 Cr in Q2 FY26. Segmental growth: Shalby Hospitals/Pharma/Franchise grew to INR 234.5 Cr (80.9% of total), Shalby MedTech (Implants) grew 42.1% YoY to INR 33.7 Cr (11.6% of total), and Shalby International (Sanar) contributed INR 19.9 Cr (6.9% of total).

Geographic Revenue Split

A significant portion of revenue is generated from Gujarat, particularly the flagship SG Highway hospital. Sanar International Hospital expands the footprint into Delhi-NCR, while international patients from 60+ countries contribute 65% of Sanar's revenue.

Profitability Margins

Consolidated OPM declined from 19.3% in FY24 to 12.2% in FY25 due to losses in Sanar and MedTech. Standalone EBITDA margin for H1 FY26 was 20.6%, down from 21.6% YoY, reflecting a 1.8% decline in core profitability.

EBITDA Margin

Consolidated EBITDA for Q2 FY26 was INR 46.1 Cr, up 15.8% YoY from INR 39.8 Cr. MedTech EBITDA grew 1795.4% YoY to INR 3.66 Cr, while Shalby International reported an EBITDA loss of INR 1.2 Cr in Q2 FY26.

Capital Expenditure

Shalby acquired Healers Hospital Private Limited (HHPL) for INR 104 Cr to transition from a leased to an owned model. Net debt is expected to increase by INR 100-105 Cr for HHPL and INR 140-145 Cr for the PKHPL acquisition.

Credit Rating & Borrowing

ICRA revised the long-term rating from [ICRA]A+(Stable) to [ICRA]A+(Negative) due to margin deterioration. Gross borrowings stood at INR 129.44 Cr as of September 2025 with a net debt of INR 30.93 Cr.

⚙️ Operational Drivers

Raw Materials

Orthopedic implants (knee/hip), surgical consumables, and pharmaceutical medicines represent the primary material costs, with materials and consumables accounting for 25.9% of total revenue in Q2 FY26.

Import Sources

Implants are manufactured in-house via Shalby Advanced Technologies (SAT) in the USA (Consensus Orthopedics assets) and sourced for domestic use in India.

Key Suppliers

Shalby MedTech (internal subsidiary) serves as a key supplier for implants; other pharmaceutical and consumable suppliers are not specifically named in the documents.

Capacity Expansion

Sanar International Hospital has a total bed capacity of 130. Group-wide occupancy was 47.5% in 9M FY25, while Sanar operated at a low 21% occupancy in Q2 FY26.

Raw Material Costs

Materials and consumables costs were 25.9% of revenue in Q2 FY26. Procurement strategies include in-house manufacturing of implants to reduce external sourcing costs and improve supply chain control.

Manufacturing Efficiency

MedTech sold 10,988 implant components in Q2 FY26, a 16.4% YoY increase. Hospital efficiency is constrained by low occupancy at Sanar (21%) and emerging specialty units.

📈 Strategic Growth

Expected Growth Rate

16-20%

Growth Strategy

Growth will be driven by scaling the MedTech implant division (expected 50% YoY growth), increasing international patient footfall at Sanar (currently 65% of its revenue), and diversifying into non-arthroplasty segments like oncology and transplants.

Products & Services

Arthroplasty (joint replacement) surgeries, knee and hip implants, liver/kidney/bone marrow transplants, and cardiac care services.

Brand Portfolio

Shalby, Sanar International, Shalby Academy, Slaney, Griffin, and Consensus Orthopedics (acquired assets).

New Products/Services

MedTech is planning to launch new implant products in FY26, which is expected to drive the projected 50% revenue growth in that segment.

Market Expansion

Expansion into the Delhi-NCR market via Sanar and increasing the number of Shalby Orthopedics Centres of Excellence (SOCEs) across India.

Market Share & Ranking

Shalby is a leading player in the Indian arthroplasty (joint replacement) market, though specific market share % is not disclosed.

Strategic Alliances

Strategic acquisition of Healers Hospital (HHPL) and PK Healthcare (Sanar) to consolidate the Delhi-NCR presence.

🌍 External Factors

Industry Trends

The industry is shifting toward multi-specialty care and digital accreditation (Digital NABH). Shalby is positioning itself by diversifying beyond its core arthroplasty strength into transplants and oncology.

Competitive Landscape

Competes with major multi-specialty hospital chains and specialized orthopedic clinics.

Competitive Moat

The primary moat is the brand reputation of Dr. Vikram Shah in arthroplasty and the high switching costs/technical expertise required for complex joint replacements.

Macro Economic Sensitivity

Healthcare demand is sensitive to per capita income growth and widening medical insurance coverage, which increases the affordability of elective surgeries.